Cambridge Antibody Technology has retained the top slot, ahead of Oxford GlycoSciences, in the PricewaterhouseCoopers bioscience index and share league for the first two months of 2001.
Top slot for CAT
Other Mid-Anglia runners include Alizyme at number five, up two places, Phytopharm at number nine, down from number four, Newmarket-based GeneMedix up one at 12, Weston Medical down one at 13.
Celltech stays at 21, Acambis (formerly Peptide) at 27, up three places, Pharmagene down one at 29, CeNeS up one at 33, swopping places with Cantab.
Celsis is placed up one at 38, just ahead of British Biotech.
PwC says: 'The index highlights the performance of UK bioscience companies compared with the FTSE All-Share index.
'Despite underperforming against the FTSE All-Share until late 1999, the Bioscience index has now moved to a 28 point advantage.
'It has decreased during the past two months and is 178 per cent of its value at August 1996.'